SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
SAN DIEGO, March 07, 2018 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its year end 2017 financial results on Monday, March 19, 2018 after the close of the U.S. financial markets. Company management will host a conference call and webcast on Monday, March 19, 2018 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the results and provide a corporate update.
Interested parties may access the call by dialing toll-free (844) 358-9116 from the US or (209) 905-5951 internationally and using conference ID 3697758.
The press release and links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts. An audio replay will be available for at least 90 days following the event.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and development of innovative medicines using its knowledge of newly discovered pathways in immunology effected by extracellular tRNA synthetases. To date, aTyr has generated innovative and unique development programs based on its knowledge of extracellular histidyl-tRNA synthetase (HARS), known as the Resokine pathway. aTyr’s clinical stage ATYR1923 (iMod.Fc) program is an agonist of the Resokine pathway designed to temper immune engagement in interstitial lung diseases. aTyr’s preclinical research stage ORCA program, targets a novel, proprietary immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 250 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein compositions derived from tRNA synthetase genes. For more information, please visit http://www.atyrpharma.com.
Contact:
Mark Johnson
Sr. Director, Investor Relations
[email protected]
858-223-1163
